[An update on recent developments in non-Hodgkin's lymphoma]

Area of Science:

• Hematology
• Oncology
• Medical Imaging

Background:

• Non-Hodgkin's lymphoma (NHL) management has evolved significantly over 15 years.
• Prognostic factors led to the International Non-Hodgkin's Lymphoma Prognostic Factors Index (IPI) and gene array studies.
• Therapeutic strategies now focus on intensified regimens and novel agents for adverse prognostic factors.

Purpose of the Study:

• To review recent significant improvements in the management of lymphomas.
• To highlight advancements in therapeutic approaches and diagnostic modalities for NHL.

Main Methods:

• Review of therapeutic advancements, including monoclonal antibodies (MoAb) and radiolabeled antibodies.
• Evaluation of diagnostic improvements, particularly positron emission tomography (PET) in staging and response assessment.
• Discussion of intensified chemotherapy regimens compared to the classical CHOP regimen.

Main Results:

• Monoclonal antibodies, such as rituximab, have dramatically improved response rates in diffuse large B-cell lymphoma and follicular lymphoma.
• Radiolabeled antibodies enhance therapeutic potency by targeting CD20+ cells and protecting normal organs.
• PET imaging offers high accuracy for detecting residual disease and extranodal localizations, serving as a key non-invasive assessment tool.

Conclusions:

• Modern NHL management incorporates targeted therapies and advanced imaging for improved patient outcomes.
• Monoclonal antibodies and radiolabeled antibodies represent significant therapeutic progress.
• PET imaging is crucial for accurate staging and response evaluation in NHL.